Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
出版年份 2013 全文链接
标题
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 24, Issue 7, Pages 1900-1907
出版商
Oxford University Press (OUP)
发表日期
2013-03-22
DOI
10.1093/annonc/mdt109
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study.
- (2017) J. Sarantopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).
- (2017) A. Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A Simple and Sensitive LC–MS/MS Method for Simultaneous Determination of Temsirolimus and Its Major Metabolite in Human Whole Blood
- (2012) Xianhua Zhang et al. CHROMATOGRAPHIA
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
- (2012) K. A. Margolin et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
- (2012) M. A. Davies et al. CLINICAL CANCER RESEARCH
- Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma
- (2012) Thomas Decaens et al. DIGESTIVE AND LIVER DISEASE
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors
- (2012) Edward H Cho et al. PHYSICAL BIOLOGY
- Activation of PI3K/AKT and MAPK Pathway through a PDGFRβ-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma
- (2012) Quan-Lin Li et al. PLoS One
- Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice
- (2012) S. Menon et al. Science Signaling
- A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
- (2011) Andrea L. Harzstark et al. CANCER
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
- (2011) T. C. Gangadhar et al. CLINICAL CANCER RESEARCH
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation
- (2011) Roberto Gedaly et al. JOURNAL OF SURGICAL RESEARCH
- Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis
- (2011) Wenhua Liang et al. LIVER TRANSPLANTATION
- Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
- (2011) Carlos Gomez-Martin et al. LIVER TRANSPLANTATION
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
- (2011) Teiji Kuzuya et al. ONCOLOGY
- Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
- (2009) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
- (2009) Pippa Newell et al. JOURNAL OF HEPATOLOGY
- The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
- (2009) Ledu Zhou et al. MEDICAL ONCOLOGY
- Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma
- (2008) Z. Wang et al. CLINICAL CANCER RESEARCH
- Utility of Lens culinaris Agglutinin-Reactive Fraction of α-Fetoprotein and Des-Gamma-Carboxy Prothrombin, Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma
- (2008) Richard K. Sterling et al. Clinical Gastroenterology and Hepatology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
- (2008) Stephen L. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
- (2008) Viraj J. Jasinghe et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search